{"filings":[{"id":2078959,"accession_number":"0001193125-26-335098","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-08-05T20:10:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.","Cash and equivalents $78.1M as of June 30, 2026; runway extended through Q3 2027 including $10M Alnylam upfront.","Positive interim data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) trials: all evaluable patients showed improvements in hypertrophy and electrical stability.","Additional data and regulatory discussions on pivotal trial plans for TN-201 and TN-401 expected in Q4 2026.","Appointed Eric Hyllengren as CFO effective July 13, 2026; TN-301 Phase 2 trial expected to start 2H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1417127,"accession_number":"0001193125-26-294879","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-07-02T21:00:17+00:00","items":["1.02"],"status":"ready","headline":"Tenaya Therapeutics terminates lease for GMMC Facility; forfeits $1.75M deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated lease for 94,046 sq ft GMMC Facility in Union City, CA; original expiry July 2031, now ends Aug 31, 2026.","Forfeited $1.75M security deposit and paid ~$294,200 one-time termination fee.","Facility decommissioned in 2025 to reduce costs; ongoing trials supported by existing TN-201 and TN-401 inventory.","Plans to transfer AAV manufacturing process to a CDMO for late-stage development and commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1316076,"accession_number":"0001193125-26-286957","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-06-29T13:00:16+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.","Hyllengren receives $490k base salary, 40% target bonus, option to purchase 1.65M shares.","SVP Finance Tomohiro Higa to retire in Q3 2026; will remain as consultant for transition.","CEO Faraz Ali and Tomohiro Higa cease as interim PFO and acting PAO as of July 13.","Hyllengren brings 20+ years experience in biotech finance, capital markets, corporate strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748757,"accession_number":"0001193125-26-248680","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-05-29T21:04:54+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Tenaya shareholders approve amended equity plan adding 6.5M shares, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2021 Equity Incentive Plan with one-time increase of 6,509,966 shares (~3% of outstanding).","Annual evergreen cap removed; future yearly increase remains 4% of outstanding shares per fiscal year.","Class II directors Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen elected with >86M votes each.","Deloitte & Touche ratified as independent auditor for FY2026 with 135.6M votes for.","Plan amendments also limit shares issuable as incentive stock options to 15M total."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96328,"accession_number":"0001193125-26-208975","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.","Alnylam collaboration: $10M upfront, up to $1.1B milestones; cash runway into H2 2027 inclusive of upfront.","TN-201 (HCM gene therapy): interim Cohort 2 data and Cohort 1 update expected Q2 2026; enrollment resumed after protocol amendments.","TN-401 (ARVC gene therapy): one-year Cohort 1 and initial Cohort 2 data to be presented at ASGCT May 15, 2026.","TN-301 (HDAC6i) granted Rare Pediatric and Orphan Drug Designation for DMD; preclinical data showed improved grip strength."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":225000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110142,"accession_number":"0001193125-26-102170","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.","Cash, equivalents and investments $100.5M at Dec 31, 2025; December offering net $55.8M plus Alnylam upfront extend runway into H2 2027.","TN-201 (HCM) and TN-401 (ARVC) gene therapies: interim data presented; enrollment resumed; plans for regulatory alignment in 2026.","Entered multi-target collaboration with Alnylam: $10M upfront, up to $1.1B milestones; Alnylam handles development and commercialization.","TN-301 (HDAC6i) preclinical DMD data: improved grip strength to wild-type levels at 3 mg/kg, outperforming givinostat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110141,"accession_number":"0001193125-26-092654","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.","Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.","Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.","Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.","Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110140,"accession_number":"0001193125-26-032017","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.","Company has 180 days, until July 27, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive business days.","If not cured, Tenaya may transfer to Nasdaq Capital Market for second 180-day compliance period, subject to eligibility and application.","Board approved increase in Inducement Plan shares by 2,161,000 to a total of 3,361,000 shares for new-hire equity grants.","Inducement Plan amendment effective Jan 26, 2026; awards limited to new employees as material inducement under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110139,"accession_number":"0001193125-26-001065","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David Goeddel resigns from Tenaya board effective Jan 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Goeddel submitted resignation from the Board and all committees on Dec 31, 2025. Effective Jan 26, 2026.","Resignation due to retirement; no disagreement with Company on operations, policies, or practices.","Board thanked Dr. Goeddel for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126685,"accession_number":"0001193125-25-317642","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices $60M public offering of 50M units at $1.20/unit; warrants at $1.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$60M from 50M units, each unit = 1 share + 1 warrant (5-yr, $1.50 exercise).","Underwriters: Leerink Partners, Piper Sandler, LifeSci Capital. Closing expected Dec 15, 2025.","Proceeds to fund development of TN-201 and TN-401 and for working capital and general purposes.","Warrant coverage at 100%; shares and warrants immediately separable on issuance.","60-day lockup for officers, directors, and certain stockholders unless consent is given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126684,"accession_number":"0001193125-25-315951","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on TN-201; TN-401 shows positive interim data in ARVC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA removed clinical hold on MyPEAK-1 trial for TN-201 gene therapy; protocol amendments implemented, dosing to resume.","TN-401 well tolerated at 3E13 vg/kg; no dose-limiting toxicities or thrombotic microangiopathy observed.","Robust transduction and PKP2 protein increase in 2 of 3 patients; vector copy numbers 3.4 and 5.0 per genome.","Clinically meaningful arrhythmia reduction: Patient 1 PVCs -46%, Patient 2 PVCs -89% and NSVT from 78 to 0.","One-year Cohort 1 and early Cohort 2 data for TN-201 and TN-401 expected in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126683,"accession_number":"0001193125-25-273230","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q3 net loss $20.3M; FDA places clinical hold on TN-201 MyPEAK-1 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $20.3M ($0.12/share) vs $25.6M ($0.30) in Q3 2024; cash $56.3M, sufficient into H2 2026.","FDA placed clinical hold on MyPEAK-1 trial of TN-201 (MYBPC3 HCM) after proactive FDA outreach; company expects resolution without impacting timelines.","New TN-201 data at AHA: Cohort 1 patients at ≥52 weeks showed durable reductions in hypertrophy and biomarkers; dose-dependent MyBP-C protein expression.","TN-401 (PKP2 ARVC) completed dosing in Cohort 2 (6E13 vg/kg); DSMB positive for expansion; Cohort 1 data expected Q4 2025.","DSMB recommended dose expansion for TN-201 after positive safety review; no new meaningful safety events since review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126682,"accession_number":"0001193125-25-272423","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.","Clinical hold based on data previously reviewed by DSMB in summer 2025; DSMB found acceptable safety profile for expansion cohorts.","TN-201 generally well tolerated; no new meaningful safety events since DSMB review.","Tenaya working collaboratively with FDA to resolve hold; expects no impact on data milestones or development timelines.","Company intends to resume dosing once protocol changes are implemented at trial sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143466,"accession_number":"0000950170-25-104164","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.","Cash, equivalents and marketable securities $71.7M as of June 30, 2025; runway into H2 2026.","TN-201 for HCM: Cohorts 1 & 2 enrollment complete; DSMB allows expansion; data readout Q4 2025.","TN-401 for ARVC: Cohort 1 enrolled; DSMB recommends dose escalation; first patient dosed in Cohort 2; data Q4 2025.","R&D expense $17.4M vs $22.6M YoY; G&A $6.7M vs $8.2M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161658,"accession_number":"0000950170-25-079773","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenaya Therapeutics shareholders elect all three Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Goeddel, Ph.D. elected with 80,444,762 votes for, 8,262,596 withheld.","Jeffrey T. Walsh elected with 70,717,277 for, 17,990,081 withheld.","R. Sanders Williams elected with 70,410,874 for, 18,296,484 withheld.","Ratification of Deloitte & Touche LLP passed with 120,339,858 for, 416,705 against, 192,213 abstain.","Broker non-votes of 32,241,417 on each director nominee; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161657,"accession_number":"0000950170-25-065703","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.","Cash, equivalents and investments $88.2M at March 31; March public offering netted $48.8M, extending runway into H2 2026.","TN-201 low-dose cohort showed improved NYHA class in all 3 patients and hypertrophy improvement in 2 of 3; Cohort 2 enrollment on track.","TN-401 RIDGE-1 Phase 1b enrollment on track for H1 2025; initial data expected H2 2025.","Restructuring with workforce reduction estimated at $1.6-$2.7M charges to extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161656,"accession_number":"0000950170-25-055927","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tenaya receives Nasdaq bid price deficiency notice; must regain compliance by Oct 13, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of TNYA common stock below $1.00 for 30 consecutive business days through April 12, 2025.","Nasdaq granted 180-day compliance period ending October 13, 2025; no immediate impact on listing.","To regain compliance, shares must close at $1.00 or higher for at least 10 consecutive business days.","If not cured, Company may seek a second 180-day period by transferring to Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179768,"accession_number":"0001193125-25-067071","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.","Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.","Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.","Cash runway extended into second half of 2026 via cost-containment measures.","Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179767,"accession_number":"0000950170-25-036296","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q4 2024 net loss of $23.8M; cash runway extended to mid-2026 after $48.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).","Cash and investments $61.4M at Dec 31, 2024; after $48.9M March 2025 offering, runway into mid-2026.","Dosing initiated in Cohort 2 (6E13 vg/kg) of MyPEAK-1 Phase 1b/2 trial for TN-201; Cohort 1 data accepted as ACC late-breaker.","First patient dosed in RIDGE-1 Phase 1b trial for TN-401; initial data expected in 2H25; CIRM awarded $8M grant.","Hiro Higa promoted to SVP, Finance and interim principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179766,"accession_number":"0001193125-25-045628","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices $52.5M public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.","Each unit: one share common + Series A warrant (1 share at $0.80, 5yr) + Series B warrant (0.5 share at $0.70, expires June 30, 2026).","Offering expected to close March 5, 2025; Leerink Partners and Piper Sandler are joint book-runners.","Net proceeds to fund development of TN-201 and TN-401, and for working capital.","Company also terminated ATM prospectus under existing sales agreement with Leerink Partners as of March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179765,"accession_number":"0000950170-25-016378","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya appoints interim PAO and reprices CEO underwater options to $1.21","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tomohiro Higa appointed Interim Principal Accounting Officer effective Feb 6, 2025; he remains SVP Finance.","Board repriced CEO Faraz Ali's underwater options: new exercise price $1.21 per share on 915,875 shares.","Prior exercise prices ranged from $5.64 to $15.19; repricing contingent on retention through July 24, 2025.","If CEO exercises before retention date, he must pay the original higher exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179764,"accession_number":"0000950170-25-009946","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics reprices underwater employee stock options to $1.21 per share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Repriced ~4.1M shares of underwater options with original exercise prices $3.06-$21.01 to $1.21 per share.","CMO Whit Tingley's options for 630,982 shares repriced from $3.06-$15.19 to $1.21.","Early exercise requires paying original higher exercise price until Retention Goal (July 24, 2025 or Change in Control).","No change to expiration dates, vesting criteria, or share count; total eligible options cover 4,133,517 shares.","Repricing designed to retain employees without dilutive new grants or cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196534,"accession_number":"0001193125-24-280112","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.","Robust cardiac transduction at Week 8 above preclinical efficacy levels; TN-201 mRNA increased 50% at Week 52 in Patient 1.","MyBP-C protein level increased 3% from Week 8 to 52 in Patient 1; baseline biopsies added for future quantification.","Clinical measures mostly stable/improved: NT-proBNP stable, troponin I normalized in Patient 2; NYHA class improved.","Further data from Cohort 1 and higher-dose Cohort 2 expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196533,"accession_number":"0001193125-24-280092","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics' SVP & Interim PAO Chihiro Saito resigns effective Dec 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chihiro Saito resigned as SVP, Accounting and Financial Operations and Interim Principal Accounting Officer.","Resignation is to pursue another opportunity; not due to any disagreement with Tenaya.","No replacement or timeline for successor announced in the filing.","Departure leaves interim accounting leadership role vacant at the biotech firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196532,"accession_number":"0000950170-24-122342","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.","Cash and investments $79.5M; runway expected into H2 2025.","DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.","Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.","Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212836,"accession_number":"0000950170-24-106817","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics adopts 2024 Inducement Plan, reclassifies director to balance board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Karah Parschauer reclassified from Class I to Class II director to balance board classes (3 per class).","Board reduced size to 9 directors; Parschauer's compensation unchanged, remains on Audit Committee.","Adopted 2024 Inducement Equity Incentive Plan, reserving 1,200,000 shares for new-hire inducement awards.","Plan intended as material inducement for new employees; no shareholder approval required under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212835,"accession_number":"0000950170-24-093991","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.","Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.","TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.","TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.","CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212834,"accession_number":"0001193125-24-184817","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics CFO Leone Patterson resigning effective Aug 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leone Patterson, Chief Financial and Business Officer, resigns to pursue another opportunity; will remain until August 14, 2024.","Resignation is not due to any disagreement with Tenaya on financials, operations, policies, or practices.","Company has initiated a search for a new Chief Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231893,"accession_number":"0000950170-24-078585","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tenaya Therapeutics Director Jin-Long Chen Resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jin-Long Chen resigned as a director of Tenaya Therapeutics on June 25, 2024.","Chen also stepped down from the Corporate Governance & Nominating Committee.","Resignation was voluntary and not due to any disagreement with the company or board.","Ticker TNYA on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231892,"accession_number":"0000950170-24-067318","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenaya stockholders elect three Class III directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Faraz Ali elected with 60,262,398 votes for, 157,949 withheld; broker non-votes 10,386,279.","June Lee elected with 60,205,014 for, 215,333 withheld; broker non-votes same.","Deepak Srivastava elected with 53,643,731 for, 6,776,616 withheld; broker non-votes same.","Ratification of Deloitte & Touche as independent auditor passed: 70,778,448 for, 16,045 against, 12,133 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231891,"accession_number":"0000950170-24-059539","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01","2.05"],"status":"ready","headline":"Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.","Cash $122.2M at Mar 31; Feb follow-on raised $46.8M net; runway into H2 2025.","Workforce reduced ~22% with $1.3-1.5M severance charges expected in Q2 2024.","TN-201 initial Phase 1b data expected H2 2024; TN-401 RIDGE-1 sites activated.","Hired Dr. Whedy Wang as SVP Biometrics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250184,"accession_number":"0000950170-24-032826","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).","Cash, equivalents and investments $104.6M at Dec 31, 2023; Feb 2024 financing adds $46.5M net, extending runway into H2 2025.","Initial safety and biomarker data from MyPeak-1 Phase 1b of TN-201 for MYBPC3 HCM expected H2 2024; first patient dosed Oct 2023.","RIDGE-1 Phase 1b of TN-401 for PKP2 ARVC on track to dose first patient H2 2024; FDA Fast Track granted Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250183,"accession_number":"0001193125-24-027611","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices $50M public offering of 8.9M shares and pre-funded warrants at $4.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds expected ~$50M from 8,888,890 common shares at $4.50 and 2,222,271 pre-funded warrants at $4.499.","Offering includes participation from The Column Group, RA Capital, BlackRock, and other investors.","Expected to close February 12, 2024; Leerink Partners and TD Cowen are joint book-running managers.","Pre-funded warrants exercisable at $0.001 per share immediately until fully exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267720,"accession_number":"0000950170-23-061123","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.","First patient dosed in MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM.","FDA cleared TN-401 IND for PKP2-ARVC and granted Fast Track designation in Nov 2023.","Positive Phase 1 data for TN-301 (HDAC6 inhibitor) in HFpEF presented at HFSA 2023.","EMA granted Orphan Medicinal Product designation for TN-401 in Sep 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284946,"accession_number":"0000950170-23-040628","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $151.6M; runway into first half 2025.","R&D expense $26.5M; G&A expense $8.6M; net loss $0.45/share.","First patient in MyPeak-1 Phase 1b trial of TN-201 expected in Q3 2023.","Data from TN-301 Phase 1 trial accepted for HFSA October 2023.","IND for TN-401 PKP2 gene therapy planned for H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304746,"accession_number":"0000950170-23-027497","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Tenaya amends severance plan: CEO gets 12-18 months salary; shareholders approve officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Faraz Ali: non-CIC severance 12 months base; CIC severance 18 months base + 150% target bonus; COBRA up to 18 months.","Other named execs: non-CIC 9 months base; CIC 12 months base + 100% bonus; COBRA up to 12 months; equity accelerated.","Stockholders approved amendment to certificate of incorporation to limit officer personal liability for monetary damages.","Annual meeting: Directors Burroughs, Chen, Stehman-Breen elected; Deloitte & Touche ratified as independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304745,"accession_number":"0000950170-23-020588","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.","Net loss $31.7M ($0.43/share); R&D expense $25.6M, G&A $8.1M for Q1 2023.","TN-201 (gene therapy for HCM) received FDA Fast Track designation; Phase 1b to start Q3 2023.","Phase 1 dosing of TN-301 (HDAC6 inhibitor for HFpEF) complete; data expected H2 2023.","New Scientific Advisory Board members (Drs. Seidman, Marson) and Technical Advisory Board formed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324284,"accession_number":"0000950170-23-008934","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tenaya Therapeutics adopts amended bylaws with enhanced stockholder nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Enhanced disclosure requirements for stockholder director nominations and business proposals.","Updated provisions to address universal proxy rules and conform to Delaware General Corporation Law amendments.","Revised procedures for stockholder meetings, quorum, and adjourned meetings.","Clarified exclusive forum provisions and updated director, committee, and officer sections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324283,"accession_number":"0000950170-23-007376","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Tenaya says SVB exposure minimal; loss immaterial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maintains operating accounts at SVB with minimal balance relative to total cash and investments.","Believes exposure to loss from SVB receivership is immaterial.","No specific dollar amount disclosed; total cash position not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324282,"accession_number":"0000950170-23-006713","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.","Cash and investments $204.2M at year-end; runway expected into first half 2025.","TN-201 IND for MYBPC3 gene therapy cleared by FDA; Phase 1b dosing planned Q3 2023.","TN-301 MAD stage dosing commenced; Phase 1 data from SAD/MAD expected H2 2023.","TN-401 (PKP2 gene therapy) IND submission planned for H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342215,"accession_number":"0000950170-22-026162","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.","Amy Burroughs appointed Class II director, term expiring at 2023 annual meeting.","Burroughs receives annual cash retainer of $35,000 plus $7,500 for audit committee; granted option for 40,000 shares vesting monthly over 3 years.","Burroughs is President & CEO of Cleave Therapeutics, brings >20 years healthcare/biotech experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342214,"accession_number":"0001193125-22-287687","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics prices public offering of ~28.85M shares/warrants for ~$75M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 22,613,307 common shares at $2.60 and 6,236,693 pre-funded warrants at $2.599 per warrant.","Gross proceeds expected ~$75M before expenses; underwriters have 30-day option for up to 4,327,500 additional shares.","Offering expected to close Nov 21, 2022; joint book-runners: Morgan Stanley and Piper Sandler.","Pre-funded warrants have exercise price of $0.001 per share; all securities sold by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342213,"accession_number":"0000950170-22-024496","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.","R&D expenses $23.8M, G&A $7.5M; net loss $30.7M ($0.74 per share).","Dosing started in Phase 1 trial for TN-301 (HDAC6 inhibitor for HFpEF); data expected in 2023.","Plans to submit IND for TN-201 (MYBPC3 gene therapy for HCM) by year-end 2022; IND for TN-401 in 2023.","USPTO granted patent for TN-201 covering AAV therapy with MYBPC3; patent for TN-301 HDAC6 inhibitor allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358990,"accession_number":"0001193125-22-217452","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tenaya Therapeutics enters $75M at-the-market equity sales agreement with SVB Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate sales proceeds up to $75M from common stock sold through ATM program.","SVB Securities receives 3.0% commission on gross proceeds as sales agent.","Company sets parameters including price and volume; no obligation to sell shares.","Shares issued under shelf registration statement filed August 10, 2022.","Agreement can be terminated by either party on 10 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358989,"accession_number":"0000950170-22-016457","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.","Cash, equivalents and marketable securities $180.9M; expected to fund operations into H2 2023.","IND submissions for TN-201 (MYBPC3) and TN-301 (HDAC6) remain on track for H2 2022.","Manufacturing facility in Union City launched, state-licensed for cGMP drug product at 1000L scale.","Preclinical data presented on TN-401 (PKP2 gene therapy) and novel AAV capsids improving cardiac tropism."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377789,"accession_number":"0000950170-22-011496","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tenaya Therapeutics reports stockholder votes from 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class I directors elected: David Goeddel (34,063,079 for), Karah Parschauer (34,833,578), Jeffrey Walsh (34,112,810), R. Sanders Williams (34,135,556); 829,857 broker non-votes each.","Ratification of Deloitte & Touche as independent auditor for FY2022: 35,984,423 for, 148 against, 244 abstain; no broker non-votes.","All director nominees will serve until the 2025 annual meeting or until successors are elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377788,"accession_number":"0000950170-22-009350","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.","Net loss of $31.1M ($0.75/sh) for Q1 2022; R&D expense $24.2M, G&A $7.0M.","TN-201 received EU Orphan Medicinal Product designation for MYBPC3 HCM; IND expected H2 2022.","Preclinical TN-401 data at Heart Rhythm 2022 showed restored heart function, reduced arrhythmia, increased survival; IND expected 2023.","cGMP manufacturing facility in Union City expected operational H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396111,"accession_number":"0000950170-22-004414","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.","R&D expenses $54.4M in FY2021 (up from $31.1M); G&A $18.4M (up from $7.8M).","Net loss $72.7M ($4.10/share) vs $38.4M ($39.50/share) in 2020.","TN-201 IND submission for MYBPC3 HCM expected H2 2022; TN-301 IND H2 2022; TN-401 IND in 2023.","Appointed Sunita Sethi (SVP Regulatory) and Naymisha Patel (SVP Quality); cGMP facility in Union City to be operational H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415108,"accession_number":"0001193125-21-365119","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics appoints Karah Parschauer to Board and Joanna Auch as SVP of People and Culture","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 10 members; Karah Parschauer appointed as Class I director and audit committee member.","Parschauer receives $35k annual cash retainer, $7.5k audit committee retainer, and ~$320k stock option grant.","Joanna Auch appointed as SVP of People and Culture; previously Head of HR North America at Santen.","Both appointments effective December 22, 2021; Parschauer's term expires at 2022 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415107,"accession_number":"0001193125-21-336078","cik":1858848,"company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.","Dr. Lee receives annual cash retainer of $35,000 and stock option grant with ~$320,000 fair value.","Dr. Lee most recently CEO of Esker Therapeutics; previously EVP at MyoKardia advancing cardiomyopathies.","Dr. JeenJoo Kang resigned voluntarily, not due to any disagreement, to focus on CEO role at Appia Bio.","Company highlights transition to clinical-stage and Dr. Lee's relevant development experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":170864913.29276606,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-22T23:59:59+00:00|415107"}